Newscast – Page 80 – media

Study reveals combination of various genetic factors influence migraine risks

An investigation on 2 different theories about the hereditary ways in which migraines are found in family lines was conducted by a transatlantic team.
- Source: Ddu
- 611
- May 7, 2018
migraine Researches
PCORI funded $6.5 million to the California and San Francisco University.

The Patient-Centered Outcomes Researcher Institute (PCORI), a study to look at more effective ways to tackle uncontrolled hypertension using mHealth, was funded $6.5 million to the researchers of the University of California and San Francisco. The research includes whether the patients can care for themselves better at home through mHealth devices, compare to the doctors’ office.
- Source: Ddu - Jophy Joseph
- 562
- May 7, 2018
hypertension mHealth resea
Moderna and Merck Expand mRNA Cancer Vaccines Collaboration

Expansion Includes the Joint Development of Moderna’s KRAS Oncogene Program and Other Potential mRNA Cancer Vaccines; Merck to Make Equity Investment in Moderna
- Source: investors.merck
- 537
- May 7, 2018
Merck mRNA cancer vaccines
Shingrix approved in Europe and Japan for the prevention of shingles in adults aged 50 and over

The only shingles vaccine to achieve ≥90% efficacy across all age groups studied
- Source: gsk
- 648
- May 7, 2018
EC GSK post-herpetic neuralgia Shingrix
Healthcare sector startups to watch in 2018

Lately, Biotech and immunotherapy have been widely covered by media, but there’s more to healthcare than taking leaps of faith on new tech. New companies are addressing administrative functions, personalized medicine, and proactive wellness in their approach to the health industry.
- Source: Crunchbase
- 828
- May 7, 2018
healthcare Market Views
OpenMedReady to validate Patient identity & data Integrity for RPM

Several Mobile-Health companies are joining hands to create a clinician-facing platform for assuring data quality and patient identification in remote patient monitoring programs.
- Source: mHealth Intelligence
- 762
- May 7, 2018
digital health mHealth Researches
Flatiron Health, acquired By Roche, Signs Three-Year Deal with Bristol-Myers

Flatiron announced a three-year agreement with Bristol-Myers Squibb (BMS) a leading pharma company from the US. BMS is planning to use Flatiron’s expertise to expand real-world evidence to develop Bristol’s experimental cancer drugs.
- Source: drugdu
- 683
- May 4, 2018
BMS Company Insights Roche
Harvard’s Wyss Institute partners with Cellectis to recode the human genome

Recode project will use Cellectis’ TALEN gene editing technology to create first virus-resistant human cells for manufacturing therapeutics and developing new cell-based therapies
- Source: immunotherapies
- 664
- May 4, 2018
CAR T-cells Cellectis immunotherapies Market Views
Robust start to 2018 for Roche, as group sales grow by 6%

In the first quarter of 2018, Swiss pharmaceuticals and diagnostics player Roche group’s sales rose by 6% to CHF 13.6 billion. Sales in the pharma division increased by 7% CHF 10.7 billion mainly by strong growth in Ocrevus and Perjeta.
- Source: drugdu
- 835
- May 4, 2018
Company Insights Roche
Garmin Health partnering with the University of Kansas Medical Center on Innovative Digital Health Research

The University Of Kansas Medical Center is partnering with Garmin Health to foster innovation and better understand on how healthcare wearables can help in the detection and management of significant medical conditions. Their first research will focus on cardiac care and sleep apnea.
- Source: mHealth Intelligence
- 711
- May 3, 2018
digital health Researches wearables

your submission has already been received.

OK

Subscribe

Please enter a valid Email address！

Submit

The most relevant industry news & insight will be sent to you every two weeks.

more

more

Customer Services
Contact Us
Help Center

Buy on Drugdu.com
Browse Product Categories

Free APP

Follow Us

Terms & Conditions | Privacy Policy

粤ICP备16008861号

Copyright © 2016-2018 Drugdu.com. All Rights Reserved.